What is Proteon?
Proteon, a company with a long-standing expertise in developing and managing Plone applications since 2005, stands out in the Plone market due to its deep technical knowledge. With experience spanning from Plone version 2.1 upwards, Proteon possesses the capability to address complex Plone challenges, including multi-client/server infrastructures, content versioning and staging, caching, fail-over solutions, and integration with external databases via Single Sign-On. Their comprehensive understanding of both Plone's source code and its underlying infrastructure positions them as a unique and capable provider for a wide array of Plone-related needs.
How much funding has Proteon raised?
Proteon has raised a total of $122.2M across 4 funding rounds:
Series A
$12M
Series B
$50M
Unspecified
$15.2M
Series D
$45M
Series A (2007): $12M with participation from TVM Capital, Devon Park BioVentures, Intersouth Partners, and Bessemer Venture Partners
Series B (2009): $50M led by Intersouth Partners, TVM Capital, MPM Bio IV NVS Strategic Fund, Bessemer Venture Partners, and Devon Park BioVentures
Unspecified (2011): $15.2M, investors not publicly disclosed
Series D (2014): $45M featuring Devon Park BioVentures, Abingworth, Pharmstandard, TVM Capital, Deerfield, MPM Capital, Inbio Ventures, Bessemer Venture Partners, and Intersouth Partners
Key Investors in Proteon
Devon Park BioVentures
Devon Park BioVentures is an investment firm that likely focuses on early-stage biotechnology and life sciences companies, providing capital and strategic guidance to foster innovation and growth in the sector.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that supports companies developing novel medicines by providing capital and expertise, focusing on seed, early-stage, and development-stage therapeutic investments.
TVM Capital
TVM Capital Life Science is a venture capital firm specializing in innovative life science products and companies, providing capital and expertise to advance breakthrough therapies and medical products.
What's next for Proteon?
The recent major strategic investment indicates that Proteon is poised for significant scaling and market penetration. This capital infusion will likely be directed towards enhancing its service offerings, expanding its development team, and potentially exploring new market segments or technological advancements within the Plone ecosystem. The company's history of handling complex enterprise-level projects suggests a strategic focus on solidifying its leadership in specialized content management solutions.
See full Proteon company page
